Publications

View all current and historical DTaP/Tdap/Td vaccine recommendations from the Advisory Committee for Immunization Practices. Current recommendations are also listed below:

• Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019
• Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices

• Skoff TH, Faulkner AE, Liang JL,et al. Pertussis Infections among Pregnant Women in the United States, 2012-2017. Clin Infect Dis. 2020 Aug 7:ciaa1112. doi: 10.1093/cid/ciaa1112.
• Mbayei SA, Faulkner A, Miner C, et al. Severe pertussis infections in the United States, 2011-2015. Clin Infect Dis. 2019 Jul 2;69(2):218-226.
• Briere EC, Pondo T, Schmidt M, et al. Assessment of Tdap vaccination effectiveness in adolescents in integrated health-care systems. J Adolesc Health. 2018;62(6):661–6.
• McNamara LA, Skoff T, Faulkner A, et al. Reduced severity of pertussis in person with age-appropriate pertussis vaccination — United States, 2010–2012. Clin Infect Dis. 2017;65(5):811–8. 2017.
• Pinell-McNamara VA, Acosta AM, Pedreira MC, et al. Expanding pertussis epidemiology in 6 Latin American countries through the Latin American Pertussis Project. Emerg Infect Dis. 2017;23(13): doi:10.3201/eid2313.170457.
• Curtis CR, Baughman AL, Debolt C, et al. Risk factors associated with Bordetella pertussis among infants aged ≤4 months in the pre-Tdap era — United States, 2002-2005. Pediatr Infect Dis J. 2016. 2017;36(8):726–35.
• Blain A, Lewis M, Banerjee E, et al. An assessment of the cocooning strategy for preventing infant pertussis — United States, 2011. Clin Infect Dis. 2016;63(4):S221–6.
• Terranella A, Rea V, Griffith M, et al. Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine. Vaccine. 2016;34(22):2496–500.
• O’Halloran A, Lu P, Williams WW, Ding H, Meyer S. Tetanus, diphtheria, and acellular pertussis vaccination among women of childbearing age — United States, 2013. Am J Infect Contr. 2016;44(7):786–93.
• Breakwell L, Kelso P, Finley C, et al. Pertussis vaccine effectiveness in the setting of pertactin-deficient pertussis. Pediatrics. 2016;137(5):e20153973.
• Matthias J, Pritchard PS, Martin SW, et al. Sustained transmission of pertussis in a highly vaccinated preschool: A 1-5-year-old cohort. Emerg Infect Dis. 2016;22(2):242–6.
• Skoff TH, Martin SW. Impact of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccinations on reported pertussis cases among those 11 to 18 years of age in an era of waning pertussis immunity: A follow-up analysis. JAMA Pediatrics. 2016;170(5):453–8.
• Skoff TH, Kenyon C, Cocoros N, et al. Source of infant pertussis infection in the United States. Pediatrics. 2015;136(4):635–41.
• Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington state pertussis epidemic. Pediatrics. 2015;135:981–9.
• Tiwari TS, Baughman AL, Clark TA. First pertussis vaccine dose and prevention of infant mortality. Pediatrics. 2015;135:990–9.
• Gambhir M, Clark TA, Cauchemez S, Tartof SY, Swerdlow DL, Ferguson NM. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. PLoS Comput Biol. 2015;11(4):e1004138.
• Hewlett EL, Burns DL, Cotter PA, et al. Pertussis pathogenesis—what we know and what we don’t know. J Infect Dis. 2014;209(7):982–5.
• Lu PJ, Graitcer SB, O’Halloran A, Liang JL. Tetanus, diphtheria and acellular pertussis (Tdap) vaccination among healthcare personnel—United States, 2011. Vaccine. 2014;32(5):572–8.
• Matthias J, Dusek C, Pritchard PS, Rutledge L, Kinchen P, Lander M. Notes from the field: Outbreak of pertussis in a school and religious community averse to health care and vaccinations — Columbia County, Florida, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(30):655.
• Rodgers L, Martin SW, Cohn A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis — Ohio, 2010-2011. Clin Infect Dis. 2013;56:322–31.
• Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131:e1047–52.
• Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308:2126–32.
• CDC. Pertussis Epidemic — Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012;61(28):517-22.
• Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new? Trends Microbiol. 2012;20:211–3.
• Mandal S, Tatti KM, Woods-Stout D, et al. Pertussis pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA from clinic surfaces. Pediatrics.  2012;129:e424–30.
• Skoff TH, Cohn AC, Clark TA, Messonnier NE, Martin SW. Early impact of the US Tdap vaccination program on pertussis trends. Arch Pediatr Adolesc Med. 2012;166:344–9.
• Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KR. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine. 2010;28:8001–7.
• CDC. Tetanus and pertussis vaccination coverage among adults aged ≥18 years — United States, 1999 and 2008. MMWR Morb Mortal Wkly Rep. 2010;59(40):1302–6.
• Wei S, Tatti K, Cushing K, Rosen J, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine (Tdap) against pertussis. Clin Infect Dis. 2010;51:315–21.
• CDC. Use of mass Tdap vaccination to control an outbreak of pertussis in a high school–Cook County, Illinois, September 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2008;57(29):796–9.
• CDC. Hospital-acquired pertussis among newborns — Texas, 2004. MMWR. 2008;57(22):600–3.
• Cassiday P, Tobin-D’Angelo M, Watson J, Wu KH, Park M, Sanden G. Co-infection with two different strains of Bordetella pertussis in an infant. J Med Microbiol. 2008;57:388.
• CDC. Outbreaks of Respiratory Illness Mistakenly Attributed to Pertussis — New Hampshire, Massachusetts, and Tennessee, 2004–2006. MMWR Morb Mortal Wkly Rep. 2007; 56(33):837–842.
• CDC. Pertussis outbreak in an Amish community — Kent County, Delaware, September 2004–February 2005. MMWR Morb Mortal Wkly Rep. 2006;55(30):817–21.
• CDC. Pertussis — United States, 2001-2003. MMWR Morb Mortal Wkly Rep. 2005;54(50):1283–86.
• CDC. Outbreaks of pertussis associated with hospitals — Kentucky, Pennsylvania, and Oregon, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(3):67–71.
• CDC. School-associated pertussis outbreak-Yavapai County, Arizona, September 2002-February 2003. MMWR Morb Mortal Wkly Rep. 2004;53(10):216–9.
• CDC. Fatal case of unsuspected pertussis diagnosed from a blood culture — Minnesota, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(6):131–2.
• CDC. Pertussis outbreak among adults at an oil refinery — Illinois, August–October 2002. MMWR Morb Mortal Wkly Rep. 2003;52(01):1–4.
• Brennan M, Strebel P, George H, et al. Evidence for transmission of pertussis in schools, Massachusetts, 1996: Epidemiologic data supported by pulsed-field gel electrophoresis studies. J Infect Dis. 1999;181:210–5
• CDC. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending December 19, 1998 and December 13, 1997 (50th Week). MMWR Morb Mortal Wkly Rep. 1998;47(50):1101–6.
• CDC. Case definitions for infectious conditions under public health surveillance MMWR Morb Mortal Wkly Rep. 1997;46(RR10):1–55.

• Weigand MR, Peng Y, Pouseele H, et al. Genomic surveillance and improved molecular typing of Bordetella pertussis using wgMLST. J Clin Microbiol. 2021 Feb 24:JCM.02726-20. doi: 10.1128/JCM.02726-20.
• Weigand MR, Peng Y, Batra D, et all. Conserved Patterns of Symmetric Inversion in the Genome Evolution of Bordetella Respiratory Pathogens. mSystems. 2019 Nov 19;4(6).
• Vaz-de-Lima LRA, Sato HK, Fernandes EG, et al. Association between the timing of maternal vaccination and newborns’ anti-pertussis toxin antibody levels. Vaccine. 2019;37(36):5474–80.
• Rajam G, Carlone G, Kim E, et al. Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens. Biologicals. 2019;57:9–20.
• Weigand MR, Williams MM, Peng Y, et al. Genomic survey of Bordetella pertussis diversity, United States, 2000–2013. Emerg Infect Dis. 2019;25(4):780–3.
• Ibrahim R, Ali SA, Kazi AM, et al. Impact of maternally derived pertussis antibody titers on infant whole-cell pertussis vaccine response in a low income setting. Vaccine. 2018;36:7048–53.
• Lee AD, Cassiday PK, Pawloski LC, et al. Clinical evaluation and validation of laboratory methods for the diagnosis of Bordetella pertussis infection: Culture, polymerase chain reaction (PCR) and anti-pertussis toxin IgG serology (IgG-PT). PLOS. 2018;13(4):e0195979.
• Weigand MR, Pawloski LC, Peng Y, et al. Screening and genomic characterization of filamentous hemagglutinin-deficient Bordetella pertussis. Infect Immun. 2018;86(4):e00869–17.
• Weigand MR, Williams MM, Otero G. “Temporal patterns of Bordetella pertussis genome sequence and structural evolution.” In Pertussis: Epidemiology, immunology, and evolution, edited by Pejman Rohani and Samuel Scarpino. Oxford: Oxford University Press, 2018.
• Weigand MR, Peng Y, Loparev V, et al. The history of Bordetella pertussis genome evolution includes structural rearrangement. J Bacteriol. 2017;199(8): e00806-16.
• Pawloski L, Plikaytis B, Martin M, et al. Evaluation of commercial assays for single-point diagnosis of pertussis in the US. J Ped Infect Dis Soc. 2017;6(3):e15–21.
• Gates I, DuVall M, Ju Hong, Tondella ML, Pertussis Working Group, Pawloski L. Development of a qualitative assay for screening of Bordetella pertussis isolates for pertussis toxin production. PloS One. 2017;12(4):e0175326.
• Weigand MR, Peng Y, Loparev V, et al. Complete genome sequences of four Bordetella pertussis vaccine reference strains from Serum Institute of India. Genome Announc. 2016 4(6): e01404-16.
• Weigand MR, Peng Y, Loparev V, et al. Complete genome sequences of Bordetella pertussis vaccine reference strains 134 and 10536. Genome Announce. 2016;4(5):e00979–16.
• Bowden KE, Weigand MR, Peng Y, et al. Genome structural diversity among 31 Bordetella pertussis isolates from two recent US whooping cough statewide epidemics. mSphere. 2016;1(3)e00036–16.
• Cassiday PK, Skoff TH, Jawahir S, Tondella ML. Changes in predominance of pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates, United States, 2000–2012. Emerg Infect Dis. 2016;22(3):442–8.
• Faulkner A, Skoff TH, Tondella L, Cohn A, Clark TA, Martin SW. Trends in pertussis diagnostic testing in the United States, 1990-2012. Pediatr Infect Dis J. 2016;35(1):39–44.
• Williams MM, Sen K, Weigand MR, et al. Bordetella pertussis lacking pertactin and pertussis toxin: Report of a clinical case. Emerg Infect Dis. 2016;22(2):319–22.
• Williams MM, Taylor TH Jr, Warshauer DM, Martin MD, Valley AM, Tondella ML. Harmonization of Bordetella pertussis real-time PCR diagnostics in the US, 2012. J Clin Microbiol. 2015;53(1):118–23.
• Martin SW, Pawloski L, Williams M, et al. Pertactin-negative B. pertussis strains: evidence for a possible selective advantage. Clin Infect Dis. 2015;60(2):223–7.
• Bowden KE, Williams MM, Cassiday PK, et al. Molecular epidemiology of pertussis epidemic — Washington State, 2012. J Clin Microbiol. 2014;52(10):3549–57.
• Vaz-de-Lima LR, Martin MD, Pawloski LC, et al. Serodiagnosis as adjunct assay for pertussis infection in Sao Paulo, Brazil. Clin Vaccine Immunol. 2014;21(5):636–40.
• Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio. 2014;5:e01074.
• Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin Vaccine Immunol. 2014;21:119–25.
• Harvill ET, Goodfield LL, Ivanov Y, et al. Genome sequences of 28 Bordetella pertussis U.S. outbreak strains dating from 2010 to 2012. Genome Announc. 2013;1:e01075–13.
• Tatti KM, Martin SW, Boney KO, Brown K, Clark TA, Tondella ML. Qualitative assessment of pertussis diagnostics in United States laboratories. Pediatr Infect Dis J. 2013;32:942–5.
• Tatti KM, Loparev VN, Ranganathanganakammal S, et al. Draft genome sequences of Bordetella holmesii strains from blood (F627) and nasopharynx (H558). Genome Announc. 2013;1:e0005613.
• Tatti KM, Tondella ML. Utilization of multiple real-time PCR assays for the diagnosis of Bordetella spp. in clinical specimens. Methods Mol Biol. 2013;943:135–47.
• Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Eng J Med. 2013;368:583–4.
• Rodgers L, Martin SW, Cohn A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis–Ohio, 2010-2011. Clin Infect Dis. 2013;56:322–31.
• Bottero D, Griffith MM, Lara C, et al. Bordetella holmesii in children suspected of pertussis in Argentina. Epidemiol Infect. 2013;141:714–7.
• Schmidtke AJ, Boney KO, Martin SW, Skoff TH, Tondella ML, Tatti KM. Population diversity among Bordetella pertussis isolates, United States, 1935–2009. Emerg Infect Dis. 2012;18:1248–55.
• Pawloski LC, Kirkland KB, Baughman AL, et al. Does Tdap vaccination interfere with serodiagnosis of pertussis infection? Clin Vaccine Immunol. 2012;19:975–80.
• Mandal S, Tatti KM, Woods-Stout D, et al. Pertussis pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA from clinic surfaces. Pediatrics. 2012;129:e424–30.
• Kapasi A, Meade BD, Plikaytis B, et al. Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG Anti-PT ELISAs. Clin Vaccine Immunol. 2012;19:64–72.
• Tatti KM, Sparks KN, Boney KO, Tondella ML Novel multi-target real-time PCR assay for the rapid diagnosis of Bordetella species in clinical specimens. J Clin Microbiol. 2011;49:4059–66.
• Bolt F, Cassiday P, Tondella ML, et al. Multilocus sequence typing identifies evidence for recombination and two distinct lineages of Corynebacterium diphtheriae. J Clin Microbiol. 2010;48:4177–85.
• Hall AJ, Cassiday PK, Bernard KA, et al. Novel Corynebacterium diphtheriae in domestic cats. Emerg Infect Dis. 2010;16:688–91.
• Menzies SL, Kadwad V, Pawloski LC, et al. Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection. Clin Vaccine Immunol. 2009;16:1781–88.
• Tondella ML, Carlone G, Messonnier N, et al. International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007. Vaccine. 2009;27:803–14.
• Tatti K, Wu KH, Tondella ML, et al. Development and evaluation of dual-target real-time polymerase chain reaction assays to detect Bordetella spp. Diagn Micr Infec Dis. 2008;61:264–72.
• Tatti K, Slade B, Patel M, et al. Real-time polymerase chain reaction detection of Bordetella pertussis DNA in acellular pertussis vaccines. Pediatr Infect Dis J. 2008;27):73–4.
• Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis. 2008;47:328–38.
• Tatti K, Wu KH, Sanden G, et al. Molecular diagnosis of Bordetella pertussis infection by evaluation of formalin-fixed tissue specimens. J Clin Microbiol. 2006;44(3):1074–6.
• CDC. Fatal case of unsuspected pertussis diagnosed from a blood culture–Minnesota, 2003 MMWR. 2004;53(6):131–2.
• Hardwick T, Cassiday P, Weyant R, Bisgard K, Sanden G. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg Infect Dis. 2002;8:44–9.
• Hardwick T, Plikaytis B, Cassiday P, et al. Reproducibility of Bordetella pertussis genomic DNA fragments generated by Xba I restriction and resolved by pulsed-field gel electrophoresis. J Clin Microbiol. 2002;40:811–6.
• Bisgard K, Christie C, Reising S, et al. Molecular epidemiology of Bordetella pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989-1996. J Infect Dis. 2001;183:1360–7.
• Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard K, Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis. 2000;182:1402–8.
• Kurzynski TA, Boehm DM, Rott-Petri J, Schell R, Allison P. Comparison of modified Bordet-Gengou and modified Regan-Lowe media for the isolation of Bordetella pertussis and Bordetella parapertussis. J Clin Microbiol. 1998;26:2661–3.
• Brennan M, Strebel P, George H, et al. Evidence for transmission of pertussis in schools, Massachusetts, 1996: epidemiologic data supported by pulsed-field gel electrophoresis studies. J Infect Dis. 1999;181:210–5.
• Beall B, Cassiday P, Sanden G. Analysis of Bordetella pertussis isolates from an epidemic by pulsed-field gel electrophoresis. J Clin Microbiol. 1995;33:3083–6.
• Ruijs GJ, Groenendijk TW, Biever M. Shelf life of prepared Bordet-Gengou and Regan-Lowe agar plates for isolation of Bordetella pertussis. Eur J Clin Microbiol Infect Dis. 1991;10:974–8.
• Regan J, Lowe F. Enrichment medium for the isolation of Bordetella. J Clin Microbiol. 1977;6:303–9.